These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 5766091

  • 21. Quantitative measurements of L-dopa therapy in Parkinson's disease.
    Webster DD.
    Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Pharmacodynamics of 3, 4-dihydroxyphenylalanine (Dopa) in Parkinson's disease.
    Van Woert MH.
    Conn Med; 1970 Jun; 34(6):401-5. PubMed ID: 5431103
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA, Vanna S, Beasley B, Chambers R, Vogel WH.
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Treatment of Parkinson's disease with L-dopa].
    Guglielmi L, Vecchi L.
    Clin Ter; 1970 May 15; 53(3):259-69. PubMed ID: 4917328
    [No Abstract] [Full Text] [Related]

  • 31. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D.
    Schweiz Med Wochenschr; 1972 Jan 22; 102(3):88-94. PubMed ID: 4551909
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. L-dopa and the patient with Parkinson's disease.
    Fangman A, O'Malley WE.
    Am J Nurs; 1969 Jul 22; 69(7):1455-7. PubMed ID: 5192672
    [No Abstract] [Full Text] [Related]

  • 34. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT.
    Confin Neurol; 1972 Jul 22; 34(2):130-5. PubMed ID: 4666056
    [No Abstract] [Full Text] [Related]

  • 35. [Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia].
    Serrano PA, Irigoyen M.
    Prensa Med Mex; 1972 Jul 22; 37(7):246-50. PubMed ID: 4646433
    [No Abstract] [Full Text] [Related]

  • 36. L-dopa therapy in Parkinson's disease.
    Lipman IJ.
    Va Med Mon (1918); 1971 May 22; 98(5):242-8. PubMed ID: 4931138
    [No Abstract] [Full Text] [Related]

  • 37. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L, de la Garza R, Ivan-Reynoso G.
    Arch Invest Med (Mex); 1974 May 22; 5(2):105-16. PubMed ID: 4433198
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. DOPA in Parkinson's disease.
    Lancet; 1969 Apr 26; 1(7600):871-2. PubMed ID: 4180531
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.